News
TTM Technologies Buys Epiq Solutions for $1.1B to Boost Defense RF Capabilities
Key Points
- Interested in TTM Technologies, Inc.? Here are five stocks we like better.
- TTM Technologies agreed to acquire Epiq Solutions for $1.1 billion in cash, financed through debt, with
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Key Points
- Interested in Tenaya Therapeutics, Inc.? Here are five stocks we like better.
- Tenaya expects fourth-quarter updates on its TN-201 and TN-401 cardiac gene therapy programs, including
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Key Points
- Interested in Tandem Diabetes Care, Inc.? Here are five stocks we like better.
- Tandem is shifting U.S. pump distribution to pharmacies through a pay-as-you-go model designed to
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
Key Points
- Interested in TransMedics Group, Inc.? Here are five stocks we like better.
- Kidney transplantation is TransMedics’ largest growth initiative: The company estimates its OCS kidney
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
For Immediate Release
Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
The Zacks Analyst Blog Highlights Gartner, Huron Consulting, CBIZ and Information Services
For Immediate Release
Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
The Zacks Analyst Blog Highlights Walmart, Home Depot, Target, Lowe's, Deere and JP Morgan
For Immediate Release
Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
The Zacks Analyst Blog Highlights SKYY, WCLD, CLOU and FCLD
For Immediate Release
Chicago, IL – August 18, 2026 – Zacks.com announces the list of ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
The Zacks Analyst Blog Highlights Walt Disney, Parker-Hannifin and Occidental Petroleum
For Immediate Release
Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
Key Points
- Interested in TriSalus Life Sciences, Inc.? Here are five stocks we like better.
- Commercial expansion is underway: TriSalus substantially enlarged its sales force, with new
Gentherm Targets $3.5B Revenue as Modine Deal Expands Beyond Autos
Key Points
- Interested in Gentherm Inc? Here are five stocks we like better.
- Modine transaction: Gentherm expects its combination with Modine Performance Technologies to close in early Q4
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
Key Points
- Interested in TG Therapeutics, Inc.? Here are five stocks we like better.
- 908 Devices is concentrating exclusively on handheld chemical and drug detection for public safety, law
Atlassian Conference Highlights AI-Led Cloud Growth, Expanding Enterprise Demand
Key Points
- Interested in Atlassian Corporation PLC? Here are five stocks we like better.
- AI is driving Atlassian’s cloud momentum: Customers are upgrading to the Teamwork Collection for
Yalla Group Q2 Earnings Call Highlights
Key Points
- Interested in Yalla Group Limited Sponsored ADR? Here are five stocks we like better.
- Q2 revenue exceeded guidance at $82.6 million, supported by an 11.6% increase in game-services
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
Key Points
- Interested in Stoke Therapeutics, Inc.? Here are five stocks we like better.
- Stoke Therapeutics’ Phase III EMPEROR trial for Dravet syndrome has enrolled 162 patients, surpassing
Q2 Earnings Season Standout Performers: PLTR, MSFT
The Q2 earnings season continues to wind down, which has overall shown immense strength with outsized growth. There have been several standout releases during the Q2 earnings cycle, including those
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Key Points
- Interested in Scholar Rock Holding Corporation? Here are five stocks we like better.
- Scholar Rock expects an FDA decision on September 30 for apitegromab, an investigational treatment
XP Q2 Earnings Call Highlights
Key Points
- Interested in XP Inc.? Here are five stocks we like better.
- XP reported solid Q2 growth: Gross revenue rose 8% year over year to BRL 5.1 billion, adjusted earnings before taxes
BHP Group H2 Earnings Call Highlights
Key Points
- Interested in BHP Group Limited Sponsored ADR? Here are five stocks we like better.
- BHP reported a strong fiscal 2026, driven by record Western Australia iron-ore production, strong
Fabrinet Q4 Earnings Call Highlights
Key Points
- Interested in Fabrinet? Here are five stocks we like better.
- Record fiscal 2026 performance: Fabrinet’s fourth-quarter revenue rose 45% year over year to $1.316 billion, while